Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 7.24Marksans Pharma Ltd demonstrates a mixed financial performance. The company shows strong liquidity and solvency, indicating a solid ability to meet its short-term and long-term obligations. Growth is robust, driven by strong revenue and profit increases. Profitability metrics are also excellent, reflecting efficient operations and healthy margins. However, efficiency ratios are weak, suggesting challenges in asset utilization. Financial ratios also need improvement, particularly in earnings per share, dividend, and capital expenditure management. Overall, while the company exhibits financial stability and growth potential, there are areas where operational efficiency and financial management could be enhanced. The company should focus on improving its asset turnover and managing capital expenditures more effectively to improve long-term financial health.
Health Score : 7.24Marksans Pharma Ltd demonstrates a mixed financial performance. The company shows strong liquidity and solvency, indicating a solid ability to meet its short-term and long-term obligations. Growth is robust, driven by strong revenue and profit increases. Profitability metrics are also excellent, reflecting efficient operations and healthy margins. However, efficiency ratios are weak, suggesting challenges in asset utilization. Financial ratios also need improvement, particularly in earnings per share, dividend, and capital expenditure management. Overall, while the company exhibits financial stability and growth potential, there are areas where operational efficiency and financial management could be enhanced. The company should focus on improving its asset turnover and managing capital expenditures more effectively to improve long-term financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
48.55
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
34.97
P/B RATIO
4.83
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
4.96
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
20.39
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹322.4 as on Sep 1, 2026.
Growth Score : 10.00The company exhibits excellent growth, driven by strong revenue, operating profit, EPS, asset, and net income growth rates. This indicates the company is expanding its operations and profitability effectively. The company's prospects are very encouraging, reflecting its ability to capitalize on market opportunities and increase shareholder value. The company may be able to achieve higher growth rate in future.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.36 | 24.21 | 17.55 | 20.49 | 12.5 |
| Operating Profit Growth Rate | -23.82 | 31.27 | 35 | 15.25 | 13.61 |
| Earnings Per Share (EPS) Growth | -21.7 | 30.38 | 17.69 | 21.39 | 9.76 |
| Asset Growth Rate | 33.22 | 33.86 | 22.42 | 20.85 | 19.17 |
| Net Income Growth Rate | -21.76 | 41.71 | 18.87 | 21.59 | 9.66 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 9 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 10 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 11 | Shilpa Medicare Ltd | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 12 | Strides Pharma Science Ltd | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 21 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤14th Nov 25
Q2 FY26 Earnings Conference Call
BULLISH SENTIMENT
Marksans Pharma Ltd. is an Indian pharmaceutical company primarily engaged in research, manufacturing, and marketing of finished dosage forms. It focuses on various therapeutic areas, serving both domestic and international markets, particularly the UK, US, and Australia, with a strong presence in OTC and prescription drugs.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Marksans Pharma Ltd's P/E ratio (TTM) is 48.55, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Marksans Pharma Ltd's P/B ratio is 4.83, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Marksans Pharma Ltd's P/S ratio is 4.96, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Marksans Pharma Ltd's PEG ratio is 0.95.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Marksans Pharma Ltd's EV/EBITDA ratio is 20.39.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Marksans Pharma Ltd's ROE is 13.89%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Marksans Pharma Ltd's ROA is 15.57%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Marksans Pharma Ltd's ROCE is 19%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Marksans Pharma Ltd's operating margin is 20.37%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Marksans Pharma Ltd's net margin is 14.23%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Marksans Pharma Ltd's current ratio is 5.26.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Marksans Pharma Ltd's debt-to-equity ratio is 0.10.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Marksans Pharma Ltd's interest coverage ratio is 24.38.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Marksans Pharma Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Marksans Pharma Ltd's EPS is 9.76.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹322.40. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1992
Headquarters: Mumbai, Maharashtra
Core Offerings: Finished Dosage Forms, OTC Products, Prescription Drugs, CDMO Services
Stock Listing: NSE (MARKSANS), BSE (524404)
Promoter: Mark Saldanha / Marksans Pharma Ltd. Promoter Group
Marksans Pharma Ltd. was incorporated in 1992. The company expanded its manufacturing capabilities with the acquisition of a Goa facility in 2001. A significant milestone was the acquisition of UK-based Bell Sons & Co. (Druggists) Plc in 2005, enhancing its European OTC presence. Further UK expansion occurred in 2014 with the acquisition of RelonChem Limited's assets. In 2021, Marksans established a US manufacturing footprint by acquiring a facility in New York. The company continues to grow its global product portfolio across therapeutic areas.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| UK & Europe | 49% (FY23) | Operating Profit |
| USA | 31% (FY23) | Operating Profit |
| Australia & New Zealand | 11% (FY23) | Operating Profit |
| Rest of World | 9% (FY23) | Operating Profit |
UK & Europe: Represents the largest revenue contributor, driven by a strong presence in Over-The-Counter (OTC) and prescription products, supported by local manufacturing capabilities.
USA: Significant market for generic prescription drugs and OTC products, with manufacturing and regulatory compliance supporting steady growth.
Australia & New Zealand: Key focus area for niche products and established brands, leveraging existing regulatory approvals and distribution networks.
Rest of World (ROW): Includes other emerging and developed markets, contributing to geographical diversification and future growth opportunities.
Mr. Mark Saldanha - Managing Director and CEO. He founded Marksans Pharma and has been instrumental in its strategic direction, global expansion, and operational excellence for over three decades.
Marksans Pharma Inc. (USA)
Marksans Pharma (UK) Limited (UK)
Relonchem Limited (UK)
Nova Laboratories Limited (UK)
Marksans Pharma (Australia) Pty Ltd (Australia)
Bonus Issue of 1:1 shares in August 2023.
The Marksans Pharma Ltd share price today is ₹322.40 on NSE (MARKSANS), as of 26 Sept 2026.
As of 25 Sept 2026, Marksans Pharma Ltd share price is ₹322.40, with previous close ₹322.40. Today's range is ₹322.40 to ₹322.40. The 52-week range is ₹155 to ₹350.95.
As of today, Marksans Pharma Ltd's market cap is ₹14,624.06 crore (Mid Cap).
Marksans Pharma Ltd's current P/E ratio is 48.55, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.
Marksans Pharma Ltd's current P/B ratio is 4.83.
Marksans Pharma Ltd's current dividend yield is N/A. Last dividend of ₹0.50 per share was declared on 18-Aug-2023.
Marksans Pharma Ltd's EPS (TTM) is ₹9.76.
Marksans Pharma Ltd. is an Indian pharmaceutical company primarily engaged in research, manufacturing, and marketing of finished dosage forms. It focuses on various therapeutic areas, serving both domestic and international markets, particularly the UK, US, and Australia, with a strong presence in OTC and prescription drugs.
Marksans Pharma Ltd is promoted by Mark Saldanha / Marksans Pharma Ltd. Promoter Group, holding 43.87% as of 25 Sept 2026.
Marksans Pharma Ltd is listed on NSE (MARKSANS) and BSE (524404). Its next quarterly results are expected on May 2024.
Capital Efficiency & Returns
